CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | PARSHALL B LYNNE Director | Sale 10b5-1 | −2,445 | $54.17 | $132K | 8,339 |
| 2026-11-09 | PARSHALL B LYNNE Director | Sale 10b5-1 | −2,555 | $55.26 | $141K | 5,784 |
| 2026-11-03 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-11-03 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $62.93 | $220K | 153,902 |
| 2026-11-03 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 12,886 | ||
| 2026-11-02 | Blum Robert I President & CEO | Option exercise 10b5-1 | +7,500 | $10.60 | $80K | 286,044 |
| 2026-11-02 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $62.81 | $471K | 278,544 |
| 2026-11-02 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 134,245 | ||
| 2026-10-20 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-10-20 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $64.01 | $224K | 153,902 |
| 2026-10-20 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 16,386 | ||
| 2026-10-16 | Wysenski Nancy Director | Grant or award | +97 | $63.92 | $6K | 34,089 |
| 2026-10-16 | Kaye Edward M. MD Director | Grant or award | +195 | $63.92 | $12K | 10,629 |
| 2026-10-16 | Harrington Robert Arthur Director | Grant or award | +195 | $63.92 | $12K | 22,127 |
| 2026-10-16 | Daly James M Director | Grant or award | +195 | $63.92 | $12K | 3,585 |
| 2026-10-16 | WIERENGA WENDELL Director | Grant or award | +97 | $63.92 | $6K | 35,660 |
| 2026-10-16 | HENDERSON JOHN T Director | Grant or award | +352 | $63.92 | $22K | 78,712 |
| 2026-10-12 | Blum Robert I President & CEO | Option exercise 10b5-1 | +7,500 | $10.60 | $80K | 286,044 |
| 2026-10-12 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $62.88 | $472K | 278,544 |
| 2026-10-12 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 141,745 |
Page 1 of 22 · 429 trades